Compare AISP & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AISP | WHWK |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.1M | 95.2M |
| IPO Year | N/A | N/A |
| Metric | AISP | WHWK |
|---|---|---|
| Price | $3.00 | $2.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 770.3K | 168.6K |
| Earning Date | 11-17-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $12,033,886.00 | ★ $14,384,000.00 |
| Revenue This Year | $34.52 | N/A |
| Revenue Next Year | $59.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.79 | $1.39 |
| 52 Week High | $7.66 | $3.81 |
| Indicator | AISP | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 38.09 | 57.36 |
| Support Level | $2.79 | $2.30 |
| Resistance Level | $3.13 | $2.63 |
| Average True Range (ATR) | 0.22 | 0.16 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 19.45 | 74.47 |
Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.